ProQR Therapeutics (PRQR) Shares Outstanding (Weighted Average) (2021 - 2025)

ProQR Therapeutics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $92.0 million for Q4 2024.

  • For Q4 2024, Shares Outstanding (Weighted Average) rose 5.54% year-over-year to $92.0 million; the TTM value through Dec 2024 reached $92.0 million, up 5.54%, while the annual FY2024 figure was $93.2 million, 6.33% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2024 was $92.0 million at ProQR Therapeutics, up from $87.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $92.0 million in Q4 2024 and bottomed at $73.1 million in Q4 2022.
  • The 4-year median for Shares Outstanding (Weighted Average) is $80.3 million (2021), against an average of $81.4 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) dropped 0.45% in 2022 before it increased 19.25% in 2023.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $73.4 million in 2021, then dropped by 0.45% to $73.1 million in 2022, then rose by 19.25% to $87.2 million in 2023, then increased by 5.54% to $92.0 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Shares Outstanding (Weighted Average) are $92.0 million (Q4 2024), $87.2 million (Q4 2023), and $73.1 million (Q4 2022).